Subgroup analysis indicated that baricitinib 4 mg (net LSM change: 4.25 μmol/L; 95% CI, 3.38–5.12; P < .00001; I2 = 12%) for the treatment of RA significantly increased the level of ALT compared with the placebo group. This evidence concerns the gene GPT and rheumatoid arthritis.